After serving as Food and Drug Administration (FDA) commissioner for two months, Lester Crawford on Friday announced his resignation. Crawford, who served as acting commissioner for more than a year prior to being confirmed, wrote in his resignation letter that “it is time at the age of 67 to step aside.” Christina Pearson, a spokesperson for Health and Human Services Secretary Michael Leavitt, would not answer questions from reporters about whether the Bush Administration had asked Crawford to resign, saying she could not comment on “a personnel issue,” according to the New York Times.
Susan Wood, director of the FDA’s Office on Women’s Health, had just resigned several weeks ago in protest over the FDA placing politics above medical science in its decision making process on over-the-counter status for emergency contraception (EC). Senators Hillary Clinton (D-NY) and Patty Murray (D-WA) had blocked Crawford’s confirmation until Leavitt agreed to take action on EC by September 1, but then a week before the deadline Crawford and Leavitt double-crossed the Senators and announced another delay on EC.
Dr. Andrew C. von Eschenbach, director of the National Cancer Institute, will serve as interim FDA commissioner.
3/7/2014 Study Finds Continuing Gender Gap in Medical Research - Although 20 years have passed since the government instituted legislation requiring adequate female representation in medical studies, a recent study finds that a significant sex and gender gap still persists in medical research.
"Sex-Specific Medical Research: Why Women's Health Can't Wait" by researchers at the Connors Center for Women's Health and Gender Biology at Brigham and Women's Hospital and the Jacobs Institute at George Washington University Hospital finds that scientists still fail to account for differences between males and females. . . .